title: Treat cancers by targeting survivin: just a dream or future reality?
abstract: Since the discovery of survivin (BIRC5) as a cancer-related molecule by Grazia Ambrosini and Dario C. Altieri at 1997, our knowledge related to the function of this molecule has been extended from simple apoptosis inhibition to complicated, interlinked processes that involve interference of mitosis, apoptosis, autophagy, and even DNA repair recently. However, despite the growing amount of knowledge related to survivin in the last ten years, the development of survivin inhibitors or survivin-related molecular therapies is surprisingly and relatively slow as compared to other therapeutic inhibitors for cancer treatment. Here, the molecular functions of survivin and the progress of development of survivin-targeting therapies are discussed in detail. Functional differences between different survivin-specific inhibitors are discussed from both structural and biochemical point of views. This review also reveals different challenges that scientists are currently facing in the development of survivin inhibitors for clinical application. Finally, future directions for the development of survivin-targeted therapies are discussed in this review.
authors: Centre for Bioinformatics, School of Life Sciences, Pondicherry University, Kalapet, Puducherry, India.
authors: Mohane Selvaraj
authors: MS
authors: Coumar
authors: Fang-Ying
authors: FY
authors: Tsai
authors: Jagat Rakesh
authors: JR
authors: Kanwar
authors: Sailu
authors: S
authors: Sarvagalla
authors: Chun Hei Antonio
authors: CH
authors: Cheung
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis / Q000235:genetics; D004260:DNA Repair / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D007167:Immunotherapy; D051034:Inhibitor of Apoptosis Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D008938:Mitosis / Q000235:genetics; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000494:pharmacology / Q000627:therapeutic use; D057786:Peptidomimetics / Q000494:pharmacology / Q000627:therapeutic use; D000077022:Survivin
chemical_list: D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D051034:Inhibitor of Apoptosis Proteins; D016376:Oligonucleotides, Antisense; D057786:Peptidomimetics; D000077022:Survivin
keywords: BIRC5; LY2181308; SPC3042; Survivin; YM155